The current financial score of WAVE Life Sciences Ltd is 6.25. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 2.27M, representing a year-over-year decrease of 73.88%, while its net profit experienced a year-over-year decrease of 37.42%.
The current valuation score of WAVE Life Sciences Ltd is 6.32. Its current P/E ratio is -3.75, which is -53.46% below the recent high of -1.74 and -772.69% above the recent low of -32.71.
The current earnings forecast score of WAVE Life Sciences Ltd is 8.71. The average price target is 19.47, with a high of 42.00 and a low of 12.00.
The current price momentum score of WAVE Life Sciences Ltd is 4.42. Currently, the stock price is trading between the resistance level at 4.86 and the support level at 3.48, making it suitable for range-bound swing trading.
The current institutional shareholding score of WAVE Life Sciences Ltd is 7.00. The latest institutional shareholding proportion is 77.83%, representing a quarter-over-quarter decrease of 16.89%.
The current risk assessment score of WAVE Life Sciences Ltd is 4.49. The company's beta value is -1.33. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.